Mostrar el registro sencillo del ítem

dc.contributor.authorBonomi, P D
dc.contributor.authorGandara, D
dc.contributor.authorHirsch, F R
dc.contributor.authorKerr, K M
dc.contributor.authorObasaju, C
dc.contributor.authorPaz Ares, Luis Gonzaga 
dc.contributor.authorBellomo, C
dc.contributor.authorBradley, J D
dc.contributor.authorBunn, P A
dc.contributor.authorCulligan, M
dc.contributor.authorJett, J R
dc.contributor.authorKim, E S
dc.contributor.authorLanger, C J
dc.contributor.authorNatale, R B
dc.contributor.authorNovello, S
dc.contributor.authorPérol, M
dc.contributor.authorRamalingam, S S
dc.contributor.authorReck, M
dc.contributor.authorReynolds, C H
dc.contributor.authorSmit, E F
dc.contributor.authorSocinski, M A
dc.contributor.authorSpigel, D R
dc.contributor.authorVansteenkiste, J F
dc.contributor.authorWakelee, H
dc.contributor.authorThatcher, N
dc.date.accessioned2018-12-12T09:59:34Z
dc.date.available2018-12-12T09:59:34Z
dc.date.issued2018-08-01
dc.identifier.citationAnn Oncol. 2018; 29(8):1701-1709.es_ES
dc.identifier.issn0923-7534es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6820
dc.descriptionThe concept of predictive biomarkers for EGFR-directed mAbs addressed in this article were originally discussed at a meeting convened by Eli Lilly and Company that covered topics for physician education on SqCLC, for which participants, includ- ing some of the authors on this publication, received an honor- arium. This publication was developed separately from the meeting, and the authors received no payment in relation to the development of this publication. The authors would like to thank Charlene Rivera, PhD and Rob Kite, BSc (Hons), at Complete HealthVizion for assistance with writing and revising the draft manuscript on the basis of detailed feedback from all authors. Primary responsibility for the opinions, conclusions, and interpretation of data lay with the authors, and all authors approved the final version of the manuscript.es_ES
dc.description.abstractBackground: Upregulated expression and aberrant activation of the epidermal growth-factor receptor (EGFR) are found in lung cancer, making EGFR a relevant target for non-small-cell lung cancer (NSCLC). Treatment with anti-EGFR monoclonal antibodies (mAbs) is associated with modest improvement in overall survival in patients with squamous cell lung cancer (SqCLC) who have a significant unmet need for effective treatment options. While there is evidence that using EGFR gene copy number, EGFR mutation, and EGFR protein expression as biomarkers can help select patients who respond to treatment, it is important to consider biomarkers for response in patients treated with combination therapies that include EGFR mAbs. Design: Randomized trials of EGFR-directed mAbs cetuximab and necitumumab in combination with chemotherapy, immunotherapy, or antiangiogenic therapy in patients with advanced NSCLC, including SqCLC, were searched in the literature. Results of associations of potential biomarkers and outcomes were summarized. Results: Data from phase III clinical trials indicate that patients with NSCLC, including SqCLC, whose tumors express high levels of EGFR protein (H-score of ≥200) and/or gene copy numbers of EGFR (e.g. ≥40% cells with ≥4 EGFR copies as detected by fluorescence in situ hybridization; gene amplification in ≥10% of analyzed cells) derive greater therapeutic benefits from EGFR-directed mAbs. Biomarker data are limited for EGFR mAbs used in combination with immunotherapy and are absent when used in combination with antiangiogenic agents. Conclusions: Therapy with EGFR-directed mAbs in combination with chemotherapy is associated with greater clinical benefits in patients with NSCLC, including SqCLC, whose tumors express high levels of EGFR protein and/or have increased EGFR gene copy number. These data support validating the role of these as biomarkers to identify those patients who derive the greatest clinical benefit from EGFR mAb therapy. However, data on biomarkers for EGFR-directed mAbs combined with immunotherapy or antiangiogenic agents remain limited.es_ES
dc.language.isoenges_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectGROWTH-FACTOR RECEPTORes_ES
dc.subjectPHASE-III TRIALes_ES
dc.subjectCLINICAL-PRACTICE GUIDELINESes_ES
dc.subjectCISPLATIN PLUS GEMCITABINEes_ES
dc.subjectOPEN-LABELes_ES
dc.subjectSTAGE IVes_ES
dc.subject1ST-LINE THERAPYes_ES
dc.subjectFOLLOW-UPes_ES
dc.subjectCETUXIMABes_ES
dc.subjectCHEMOTHERAPYes_ES
dc.titlePredictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung canceres_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID29905778es_ES
dc.format.volume29es_ES
dc.format.number8es_ES
dc.format.page1701-1709es_ES
dc.identifier.doi10.1093/annonc/mdy196es_ES
dc.contributor.funderFundación Lilly 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1569-8041es_ES
dc.relation.publisherversionhttps://doi.org/10.1093/annonc/mdy196.es_ES
dc.identifier.journalAnnals of oncology : official journal of the European Society for Medical Oncologyes_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Investigación Clínica de Cáncer Pulmón H12O-CNIOes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional